Table 1.
Patient characteristics before iLA insertion (unless otherwise stated).
| all | iLA and ED | iLA - no ED | p | |
|---|---|---|---|---|
| patients | 61 | 21 | 40 | |
| male/female | 30 | 31 | 9 | 12 | 21 | 19 | |
| age (years) | 40 (28 to 52) | 36 (28 to 52) | 41 (28 to 49) | 0.942 |
| iLA treatment (days) | 6 (3 to 11) | 5 (2 to 9) | 7 (5 to 13) | 0.191 |
| iLA-flow after 2 h (l/min) | 1.1 (1.0 to 1.4) | 1.4 (1.3 to 1.6) | 1.1 (1.0 to 1.1) | 0.009 |
| days on ICU until iLA | 7 (3 to 15) | 8 (5 to 16) | 7 (3 to 12) | 0.880 |
| paO2 (mmHg) | 82 (70 to 98) | 77 (70 to 96) | 82 (70 to 100) | 0.97 |
| after 24 h iLA | 68 (65 to 84) | 71 (62 to 90) | 78 (68 to 83) | 0.900 |
| paCO2 (mmHg) | 100 (81 to 115) | 98 (81 to 114) | 100 (79 to 115) | 0.880 |
| after 24 h iLA | 52 (43 to 61) | 44 (53 to 59) | 56 (45 to 61) | 0.840 |
| pH | 7.15 (7.08 to 7.26) | 7.10 (7.04 to 7.15) | 7.23 (7.13 to 7.27) | 0.007 |
| after 24 h iLA | 7.38 (7.31 to 7.46) | 7.34 (7.26 to 7.35) | 7.41 (7.33 to 7.46) | 0.013 |
| Horowitz index (PaO2/FiO2) | 96 (75 to 137) | 98 (77 to 114) | 94 (67 to 144) | 0.280 |
| MAP (mmHg) | 80 (75 to 86) | 80 (70 to 85) | 80 (78 to 87) | 0.249 |
| Pmax (cmH2O) | 38 (34 to 41) | 38 (35 to 40) | 39 (32 to 42) | 0.747 |
| PEEP (cmH2O) | 8 (5 to 10) | 9 (5 to 13) | 8 (5 to 10) | 0.370 |
| Creatinine* (μmol/l) | 53 (40 to 91) | 93 (49 to 174) | 50 (37 to 73) | 0.005 |
| after 24 h iLA | 52 (34 to 78) | |||
| eGFR* (ml/min/1,73 m2) | 120 (79 to 138) | 66 (33 to 138) | 124 (100 to 140) | 0.003 |
| SOFA-Score | 11 (10 to 12) | 14 (11 to 17) | 11 (10 to 11) | < 0.0001 |
| APACHE II - Score | 32 (28 to 34) | 32 (31 to 38) | 31 (28 to 33) | 0.023 |
| Vancomycin use day 1-3 of iLA | 32% | 40% | 29% | |
| Aminoglycoside use day 1-3 of iLA | 26% | 13% | 32% | |
| 28 day survival | 33% | 19% | 40% | |
| one year survival | 18% | 5% | 25% | |
Data presented as median (interquartile ranges). *Creatinine and eGFR only from patients without ED dependence before iLA insertion.